TOBI® Podhaler®

HELP YOUR CF PATIENTS
FIGHT Pa ON-THE-GO

For patients with cystic fibrosis (CF) 6 years
and older with Pseudomonas aeruginosa (Pa)
and forced expiratory volume in 1 second
(FEV1) ≥25% and ≤80% predicted who are
not colonized with Burkholderia cepacia1

Not actual size.

Learn how TOBI Podhaler can
fit into your patient’s day.
This portable treatment can be
administered in 2 to 7 minutes*
twice a day and requires minimal
setup and cleanup.1

*As observed in a clinical trial.

Learn more

A centralized support and access program for TOBI® Podhaler® patients

LEARN MORE

SET TREATMENT EXPECTATIONS

Inform your patients about what to expect while taking TOBI® Podhaler®

LEARN MORE

ADMINISTRATION INFORMATION

Administration information and helpful tips for patients taking TOBI® Podhaler®

LEARN MORE

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced

INDICATION

TOBI® Podhaler® (Tobramycin Inhalation Powder) 28 mg per capsule is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa.

Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV1) <25% or >80% predicted, or patients colonized with Burkholderia cepacia.